Eisai Plunges as Alzheimer Drug Fails to Get FDA Panel Approval

(Bloomberg) -- Shares in Japanese drugmaker Eisai Co. plunged the most on record after the Alzheimer’s therapy it is developing with Biogen Inc. failed to gain support from a panel of U.S. Food and...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.